Dr. Olsen is an Academic Co-Founder and Head of Phosphoproteomics at Acrivon Therapeutics, Inc. He is a Professor in Quantitative Proteomics at the University of Copenhagen and Vice Director of the Novo Nordisk Foundation Center for Protein Research. Dr. Olsen is a pioneer in mass spectrometry based phosphoproteomics and its applications to decipher cell-signaling networks at a systems-wide scale, and his research interest is developing and applying phosphoproteomics technologies for comprehensive kinase drug profilings with clinical actionability. Dr. Olsen is one of the most highly cited authors in the study of protein phosphorylation and its impact on biology.
Dr. Olsen received his M.Sc. in Analytical Chemistry at the University of Southern Denmark and his Ph.D. in Biochemistry and Molecular Biology at the same place under the supervision of Professor Matthias Mann. Dr. Olsen completed his post-doctoral training in proteomics and cell signaling at the Max Planck Institute for Biochemistry in Munich. He is based in Copenhagen since 2009, where he joined the newly established Center for Protein Research, initially as Group Leader and since 2014 as Vice Director.